OLMA
Olema Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
7.00
close · 2026-10-30
value
55
cheaper than peers55
quality
81
stronger fundamentals81
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.42× | 68 |
| earnings yield, 3 years ago | -37.4% | 56 |
| earnings yield, 2 years ago | -30.6% | 56 |
| cash flow yield, 3 years ago | -13.5% | 51 |
| cash flow yield, 2 years ago | -13.7% | 51 |
| earnings yield, latest year | -26.7% | 50 |
| cash flow yield, 1 year ago | -17.1% | 50 |
| earnings yield, 1 year ago | -31.4% | 49 |
| cash flow yield, latest year | -24.0% | 41 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.8% | 74 |
| return on equity | -42.9% | 72 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $612M |
| free cash flow | -$78.8M |
| employees | 137 |
| first trade | 2020-11-19 |
| next earnings | not reported |
| fundamentals updated | 2026-07-31 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.87 | -2.20 | -2.14 | -2.62 |
| free cash flow | -$146.7M | -$104.5M | -$83.7M | -$82.4M |
| net income | -$162.5M | -$129.5M | -$96.7M | -$104.8M |
| revenue | $0 | $0 | $0 | $0 |